Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix

Rotmensch, Jacob; Senekjian, Elizabeth K.; Javaheri, Ghodratollah; Herbst, Arthur L.

doi:10.1016/0090-8258(88)90149-7

Cited by 21 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our experience with the capecitabine-cisplatin combination showed that this regimen was effective in the treatment of recurrent carcinoma of the uterine cervix with an overall clinical response rate of 50% and a complete response rate of 25%. The median survival period of 23 months is encouraging and compares favorably with other studies of cisplatin combined with infusional 5-FU in the treatment of metastatic and recurrent cervical cancer, which have reported an overall survival of 6.4–16 months [5,6,7,8,9,10]. The overall response rate also compares favorably with other studies, which have reported overall response rates of 22–61% [5,6,7,8,9,10].…”

Section: Discussionsupporting

confidence: 64%

“…Common non-hematological adverse events were hand-foot syndrome and stomatitis. This toxicity profile appears to be milder than that reported with cisplatin and 5-FU in other studies [5,6,7,8,9,10]. An explanation for the relatively modest toxicity could be the dose of cisplatin used in this study.…”

Section: Discussioncontrasting

confidence: 51%

“…An explanation for the relatively modest toxicity could be the dose of cisplatin used in this study. We chose a cisplatin dose of 50 mg/m 2 every 3 weeks, which is a relatively low dose intensity compared with previously reported regimens [5,6,7,8,9,10]. Data from Thigpen et al [24 ]in cervical cancer patients showed response was not increased when the dose was increased above 50 mg/m 2 every 3 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…The apparent synergy and lack of cross-resistance between 5-FU and cisplatin has led to the widespread use of regimens combining these agents for various types of tumor [3, 4]. Several phase II trials have evaluated the combination of cisplatin and 5-FU in cervical cancer with a reported response rate of 22–61% [5,6,7,8,9,10]. The spectrum of toxicities observed with 5-FU varies according to the dose, schedule and route of administration.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A Pilot Phase II Study of Capecitabine plus Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix

Benjapibal

Thirapakawong²,

Leelaphatanadit³

et al. 2007

Oncology

View full text Add to dashboard Cite

Background: To assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with recurrent carcinoma of the uterine cervix. Methods: Sixteen patients were treated with oral capecitabine (1,000 mg/m² twice daily, days 1–14) and intravenous cisplatin (50 mg/m² on day 1 every 3 weeks) for a maximum of six cycles. Results: Their median age was 50 years (31–74 years). Ten patients (63%) had recurrent disease outside the radiation field. The overall response rate was 50% (95% confidence interval 26–75%); 4 patients had complete response (25%). The overall response rate was 33% in patients with recurrent disease within the previous irradiated field and 60% in patients with tumor outside the irradiated field. The median time to progression was 9 months, with a median overall survival of 23 months. The majority of adverse events were mild and there were no grade 4 adverse events. Hematological toxicity was the most frequent adverse event with grade 3 neutropenia in 19% of patients. Grade 2 and 3 hand-foot syndrome occurred in 38 and 6% of the patients, respectively. There were no chemotherapy-related deaths. Conclusion: The combination of capecitabine plus cisplatin is a clinically active regimen with acceptable tolerability for patients with recurrent carcinoma of the uterine cervix.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Discussioncontrasting

confidence: 51%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Pilot Phase II Study of Capecitabine plus Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix

Benjapibal

Thirapakawong²,

Leelaphatanadit³

et al. 2007

Oncology

View full text Add to dashboard Cite

show abstract

“…When cyclic administration of cisplatin and etoposide was combined with continuous UFT administration, a CR rate of 100% was obtained. It is possible that the combination of cisplatin and UFT is synergistic, because cisplatin is known to be a biochemical modulator for fiuorinated pyrimidines, such as 5-fluorouracil (5-FU) [19], The combination of cisplatin and 5-FU has been used clinically with encouraging results [20][21][22], Judging from the weight loss observed in tumor-bearing mice, the combination of cisplatin, etoposide, and UFT was well tolerated. These results suggest that this regimen may be useful in preventing tumor recurrences.…”

Section: Discussionmentioning

confidence: 99%

Effect of Cyclic Cisplatin and Etoposide Therapy with Continuous UFT Administration on the Recurrence of Endometrial Cancer in Nude Mice

Suzuki

Aida²,

Sekiguchi³

et al. 1993

Oncology

View full text Add to dashboard Cite

Effects of cisplatin and etoposide chemotherapy and/or continuous administration of oral anticancer agent UFT following the initial chemotherapy with cisplatin and etoposide on the tumor recurrence rate were studied in endometrial cancer-bearing mice. Complete response (CR) rate of cyclic administration of cisplatin and etoposide (91 %) was significantly higher than that in the control group (60%; p < 0.05). Continuous UFT administration raised a CR rate of 75%, which was not significantly higher than that of the control group. When cyclic administration of cisplatin and etoposide was combined with continuous UFT administration, 100% of CR rate was obtained (p < 0.01). Our results suggest that cisplatin-based cyclic chemotherapy has a therapeutic effect on gynecologic malignancies and is particularly effective in preventing tumor recurrence in mice. Combining this therapy with continuous administration of an oral anticancer agent enhances its therapeutic effect.

show abstract

Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy

Lentz

Raish

Orlowski

et al. 1990

Cancer

View full text Add to dashboard Cite

Dystrophic epidermolysis bullosa is associated with a high incidence of cutaneous squamous cell carcinoma. Despite aggressive surgical treatment, metastases occur frequently, and survival is generally poor. Chemotherapy for advanced disease has usually been avoided because of the potential for severe cutaneous toxicity. Two patients with autosomal recessive dystrophic epidermolysis bullosa and advanced squamous cell carcinoma are described. Both received cisplatin-based systemic chemotherapy without significant toxicity.

show abstract

Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix

Cited by 21 publications

References 6 publications

A Pilot Phase II Study of Capecitabine plus Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix

A Pilot Phase II Study of Capecitabine plus Cisplatin in the Treatment of Recurrent Carcinoma of the Uterine Cervix

Effect of Cyclic Cisplatin and Etoposide Therapy with Continuous UFT Administration on the Recurrence of Endometrial Cancer in Nude Mice

Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy

Contact Info

Product

Resources

About